中文摘要：

目的探讨胸腺肽α1对老年B细胞性慢性淋巴细胞白血病（B cell chronic lymphatic leukemia,B-CLL）患者来源的细胞因子诱导的杀伤细胞（cytokine induced killer cells,CIK）扩增及杀瘤活性的影响。方法以胸腺肽α1作为免疫增强方案,1.6mg/d皮下注射,14d为1周期。采集4例B-CLL老年患者外周血单核细胞,每周1次,分别在应用胸腺肽α1前和应用1周期后各采集3次,在体外经干扰素-γ（IFN-γ）、白介素-2（IL-2）及抗CD3单克隆抗体诱导成CIK细胞,检测其扩增数量、效应细胞扩增倍数、淋巴细胞亚群比例及体外杀瘤活性。结果 4例在胸腺肽α1治疗前后各做12次CIK细胞培养,培养时间（13.8±1.4）d,细胞存活率95.46%±3.12%。培养后CD3＋、CD8＋、CD3＋CD8＋及CD3＋CD56＋T细胞比例均显著升高（P〈0.05）,CD3＋CD4＋T细胞比例无显著变化（P〉0.05）。胸腺肽α1治疗后,CIK细胞在扩增数量、效应细胞扩增倍数、比例及体外杀瘤活性明显高于治疗前（P〈0.05）。结论胸腺肽α1能够增强老年B-CLL患者CIK细胞体外扩增活性。

英文摘要：

Objective To study the effect of thymulin α 1 on in vitro amplification and tumoricidal activity of cytokineinduced killer （CIK） cells in elderly patients with B-cell chronic lymphocytic leukemia （B-CLL）. Methods Thymulin α 1, an immunoenhancement agent, was subcutaneously injected at the dose of 1.6mg/d, for 14 days which served as a cycle. Peripheral monocytes, collected from 4 elderly B-CLL patients, once a week followed by 3 times a week before and after thymulin α 1 was used. CIK cells were induced into CIK cells with IFN- γ, IL-2 and anti-CD3 monoclonal antibody. The number of amplified CIK cells and effectors, subgroups of lymphocytes and in vitro tumoricidal activity of CIK cells were detected. Results The CIK cells were cultured for 24 times before and after the patients were treated with thymulin α 1. The average amplification time was （13.8 ± 1.4）d and the cell survival rate was 95.46% ± 3.12%. The number of CD3^＋, CD8^＋, CD3^＋CD8^＋ and CD3^＋CD56^＋ T cells was significantly greater after culture than before culture （P〈0.05）. However, no significant difference was observed in the number of CD3^＋CD4^＋ T cells before and after culture （P〉0.05）. The number of amplified CIK cells and effectors, subgroups of lymphocytes and in vitro tumoricidal activity of CIK cells were significantly higher after thymosin α 1 treatment than before thymosin α 1 treatment （P〈0.05）. Conclusion Thymulin α1 can increase the in vitro amplification and tumoricidal activity of CIK cells in elderly patient with B-CLL.